TCRT
Alaunos Therapeutics, Inc.
There isn't enough reported data to score TCRT yet.
TCRT Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TCRT's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
TCRT PE Valuation
TCRT has no meaningful PE right now: it lost money over the past year.
TCRT Forward outlook
There aren't enough analyst estimates for TCRT to show an outlook.
TCRT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.90 | +$0.51 |
| Q1 2026 | -$2.12 | +$0.37 |
| Q4 2025 | -$2.20 | +$0.72 |
| Q3 2025 | -$2.26 | +$4.25 |
| Q2 2025 | -$2.41 | +$9.40 |
| Q1 2025 | -$2.49 | +$14.61 |
| Q4 2024 | -$2.92 | +$19.08 |
| Q3 2024 | -$6.51 | +$15.99 |
TCRT is still losing money, but far less than before: $1.90 per share over the past year, against $105.00 at its worst in early 2020.
TCRT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $3K | -25% |
| Q1 2025 | $2K | +100% |
| Q4 2024 | $4K | +300% |
| Q2 2024 | $4K | 0% |
| Q4 2023 | $1K | -91% |
| Q3 2022 | $2.9M | +631% |
TCRT's revenue has slid since its 2022 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -30233% | -11358 points |
| Q1 2025 | -54600% | +119600 points |
| Q4 2024 | -18875% | +776025 points |
| Q2 2024 | -29150% | +170400 points |
| Q1 2024 | -174200% | N/A |
| Q4 2023 | -794900% | -717436 points |
| Q2 2023 | -199550% | N/A |
| Q4 2022 | -77464% | N/A |
TCRT's operating margin was −30233% last quarter, up 143967 points from the same quarter a year ago.
TCRT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$300K | +$401K |
| Q1 2026 | -$1M | -$259K |
| Q4 2025 | -$553K | +$39K |
| Q2 2025 | -$701K | +$980K |
| Q1 2025 | -$772K | +$1.1M |
| Q4 2024 | -$592K | +$6.8M |
| Q3 2024 | -$781K | +$5.6M |
| Q2 2024 | -$1.7M | +$5.5M |
TCRT has burned cash in almost every quarter: −$3M over the past year, against −$4M the year before.
TCRT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +25% | +483K shares |
| 1 year | +45% | +755K shares |
| 3 years | +52% | +833K shares |
| 5 years | +70% | +1M shares |
| Available history | +114% | +1.3M shares |
TCRT has 2M diluted shares, up 45% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q4 2022 | — |
| Q4 2019 | $283,000 |
| Q3 2019 | — |
TCRT Net Leverage
TCRT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TCRT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.5 | Neutral |
| Stochastic | 28.6 | Neutral |
TCRT's weekly RSI is 45 (neutral) and its Stochastic is 29 (neutral).
TCRT PE vs Healthcare Sector
| Metric | TCRT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TCRT has no meaningful PE right now: it lost money over the past year.
TCRT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.61 | 0.6% above |
| 20 week MA | $1.73 | 6.4% below |
| 50 week MA | $2.43 | 33% below |
| 100 week MA | $2.50 | 35% below |
| 200 week MA | $17.4 | 91% below |
TCRT has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 91% below its 200-week average.
TCRT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $772.5 | $432.0 | -44% |
| 2021 | $432.0 | $189.0 | -56% |
| 2022 | $189.0 | $88.2 | -53% |
| 2023 | $88.2 | $10.6 | -88% |
| 2024 | $10.6 | $1.84 | -83% |
| 2025 | $1.84 | $3.23 | +76% |
| 2026 YTD | $3.23 | $1.62 | -50% |
TCRT has finished lower in five of the last six years. It's down 50% so far in 2026.